ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (0965–0992) Epidemiology & Public Health Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM
Abstract Number: 0985
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
9:00AM-11:00AM
Abstract Number: 0983
Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study
9:00AM-11:00AM
Abstract Number: 0992
Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray
9:00AM-11:00AM
Abstract Number: 0975
Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population
9:00AM-11:00AM
Abstract Number: 0990
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
9:00AM-11:00AM
Abstract Number: 0965
Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration
9:00AM-11:00AM
Abstract Number: 0970
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
9:00AM-11:00AM
Abstract Number: 0988
Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
9:00AM-11:00AM
Abstract Number: 0984
Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients
9:00AM-11:00AM
Abstract Number: 0978
Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model
9:00AM-11:00AM
Abstract Number: 0972
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
9:00AM-11:00AM
Abstract Number: 0986
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
9:00AM-11:00AM
Abstract Number: 0971
Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
9:00AM-11:00AM
Abstract Number: 0967
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
9:00AM-11:00AM
Abstract Number: 0977
Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
9:00AM-11:00AM
Abstract Number: 0973
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0989
Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort
9:00AM-11:00AM
Abstract Number: 0987
Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
9:00AM-11:00AM
Abstract Number: 0968
Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0976
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 0982
Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants
9:00AM-11:00AM
Abstract Number: 0980
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
9:00AM-11:00AM
Abstract Number: 0966
The Burden of Oligoarticular Psoriatic Arthritis in the United States
9:00AM-11:00AM
Abstract Number: 0981
Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors
9:00AM-11:00AM
Abstract Number: 0991
Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database
9:00AM-11:00AM
Abstract Number: 0969
Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study
9:00AM-11:00AM
Abstract Number: 0979
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
9:00AM-11:00AM
Abstract Number: 0974
Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology